Given the growing clinical pipeline of biologics and advantages offered by plant-derived therapeutics, such as high scalability and eukaryotic modification of proteins, plant-based expression systems have emerged as an optimal drug development platform
Roots Analysis has announced the addition of “Plant-based Biologics and Expression Systems Market, 2022-2035” report to its list of offerings.
Plants produce high-value recombinant proteins that can be used for the preparation of pharmaceutical therapeutics, as well as non-pharmaceutical products; these proteins find applications in the development of antibodies, vaccine antigens, enzymes, growth factors, research or diagnostic reagents and cosmetic ingredients. Plant-host engineering serves as a method for the production of proteins with distinct and uniform post-translational modifications (PTMs), creating opportunities for the development of biologics having relatively increased efficacy, as compared to their mammalian cell counterparts.
Key Market Insights
35+ players are currently engaged in offering plant-based expression systems
Close to 30% of the plant-based therapies are being developed by using benth as a protein expression host system. Other prominent plants used for the development of biologic drug candidates include tobacco, rice, wheat germ and tomato.
Over 40% of the plant-based expression system providers are based in North America
Within North America, the developer landscape is further dominated by players that are based in the US, representing around 30% of the total number of stakeholders located across the globe. Further, majority of companies (>65%) engaged in this market are small players (2-50 employees).
Get Detailed Report: https://www.rootsanalysis.com/reports/plant-based-biologics-and-expression-systems-market.html
More than 45 plant-based biologics have been / are being developed for the treatment of a range of clinical conditions
Over 45% of the aforementioned therapeutic candidates are under clinical evaluation, primarily being investigated in phase II studies. Examples of approved plant-based therapies include Elelyso® (developed by Protalix Biotherapeutics) and PALFORZIA® (developed by Aimmune Therapeutics).
Over 50% plant-based therapies have been / are being developed against infectious disorders
Currently, majority of such therapies (more than 35%) are being developed against the COVID-19 infection. It is also worth noting that close to 30% of the therapies have been / are being developed as vaccines.
Partnership activity in this field has increased at a CAGR of 16%, between 2018 and 2020
Interestingly, 35% of the reported deals were instances of R&D agreements, followed by licensing agreements (30%). Further, majority of the instances captured in the report were inked by players based in North America (over 50%).
>60% publications for plant-based biologics and expression systems are research articles
Close to 135 publications have received supporting grants from various organizations. Furthermore, we have conducted a proprietary timeline analysis to calculate the average number of days for a research article to move through the different steps of the process, from receiving acceptance of the authorizing organization to being published.
North America is anticipated to capture around 40% share of the global expression systems market in 2035
Around 55% of the market revenues are further expected to be generated through transient plant-based expression systems in 2035. Further, plant-based therapies developed as monoclonal antibodies are expected to occupy a larger share (25%) of the market, followed by vaccines (24%) and biosimilars (20%).
Plant-based therapies targeting infectious disorders are anticipated to capture around 35% of the global market share in 2035
Over 20% of the market revenues are expected to be generated from plant-based therapies being developed for the treatment of liver disorders, in 2035. This is followed by therapies being developed against respiratory disorders (~15%).
Request for Customization @ https://www.rootsanalysis.com/reports/plant-based-biologics-and-expression-systems-market/request-customization.html
Key Questions Answered
- Who are the key players engaged in providing plant-based expression systems?
- What are the key plant sources used by drug developers to manufacture plant-based biologics?
- Which are the key therapeutic areas for which plant-based biologics are being developed?
- What are the different proprietary technologies offered / developed by plant-based expression system providers?
- Which type of partnership models are most commonly adopted by stakeholders engaged in this domain?
- What is the relative competitiveness of different plant-based expression system providers?
- What is the evolving trend related to the focus of publications focused on plant-based biologics?
- How is the current and future market opportunity likely to be distributed across key market segments?
articlelength,updownews,livejustnews,newsalltype,thenextlaevel,justplangrow,approvedblog,letshareinfo,larablogy,updatexpert,gpforme
The financial opportunity within the plant-based expression systems and biologics market has been analyzed across the following segments:
Type of Product
- Biosimilars
- Cell Therapies
- Gene Therapies
- Monoclonal Antibodies
- Vaccines
- Others
Type of Plant
- Algae
- Barley
- Benth
- Duckweed
- Lettuce
- Maize
- Moss
- Rice
- Tomato
- Tobacco
- Wheat Germ
Type of Expression System
- Stable Expression System
- Transient Expression System
Type of Target Disease Indication
- Cirrhotic Ascites
- COVID-19
- Cystic Fibrosis
- Ebola Virus Infection
- Fabry Disease
- Gaucher Disease
- Liver Cirrhosis
- Influenza
- Peanut Allergy
Therapeutic Area
- Genetic Disorders
- Infectious Disorders
- Liver Disorders
- Respiratory Disorders
- Others
Drug Candidate
- Elelyso
- OsrHSA
- PALFORZIA
- PRX-110
- PRX-102
- Unnamed_1
- Unnamed_2
- ZMapp
Geographical Region
- North America
- Europe
- Asia
- Middle East and North Africa
- Latin America
- Rest of the World
The research includes profiles of key players (listed below); each profile features a brief overview of company, details related to its technology portfolio, recent developments (including collaborations and expansions) and an informed future outlook.
- medicago
- Leaf Expression Systems
- eleva
- iBio
- PlantForm
- G+Flas lifesciences
- Kentucky Bioprocessing
- Angany
Request for Sample: https://www.rootsanalysis.com/reports/plant-based-biologics-and-expression-systems-market/request-sample.html
Chapter Outlines
Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of plant-based biologics and expression systems market and its likely evolution in the coming future.
Chapter 3 is an introductory chapter that highlights important concepts related to plant-based expression system providers. The chapter features information on classification of plant-based expression platforms and their associated advantages. Additionally, it includes a discussion on the commonly used plant-based bioproduction systems and mechanism of plant expression platforms. Further, it features details related to several recent developments observed in this domain.
Chapter 4 includes information on more than 35 plant-based expression system providers. It features a detailed analysis on current market landscape of plant-based expression system providers, including type of plant (algae, barley, benth, duckweed, lettuce, maize, moss, rice, tomato, tobacco, and wheat germ), type of product, and type of expression system (transient and stable). Additionally, the chapter features developers’ landscape, along with information on their year of establishment, company size (small, mid-sized or large), location of headquarters and number of proprietary technologies.
Chapter 5 includes information on more than 45 plant-based biologics. It features a detailed analysis on current market landscape of plant-based biologics, including information on status of development (marketed, clinical and preclinical), target disease indication, therapeutic area (genetic disorders, infectious disorders, liver disorders, respiratory disorders, and others), type of product (antibodies (unspecified), biosimilars, cell therapies, monoclonal antibodies, proteins (unspecified), vaccines and others). The chapter also features developers’ landscape, along with information on their year of establishment, company size (small, mid-sized or large), location of headquarters and number of proprietary drug candidates.
Chapter 6 features elaborate profiles of the prominent players engaged in providing plant-based expression system technologies to drug developers. Each profile features a brief overview of the company, details related to technology portfolio, recent developments, and an informed future outlook.
Chapter 7 presents an analysis on recent collaborations and partnerships that have been inked by several stakeholders in this domain, during the period 2017-2021, covering R&D agreements, licensing agreements, commercialization agreements, product development agreements, product development and manufacturing agreement, acquisitions, and others.
Chapter 8 presents a detailed company competitiveness analysis, including a 2*2 matrix comparing the key players engaged in the domain of plant-based expression systems, based on several relevant parameters (such as company experience, portfolio strength, partnership activity and company size). In addition, it features a spider web representation illustrating benchmarking of players based on portfolio strength and partnership activity of key players.
Chapter 9 presents an insightful analysis of more than 1,000 peer-reviewed scientific articles related to plant-based biologics, published between 2000-2021, highlighting the research focus within this niche industry segment. It also features, key trends observed across the aforementioned publications including analysis based on several relevant parameters, such as year of publication, type of article, journal title, primary funding body, publisher, primary author, journal impact factor and analysis based on timeline. Further, the chapter also highlights a multivariate publication attractiveness analysis based on various parameters such as type of article, grant support, journal impact factor and timeline of publications.
Chapter 10 presents a detailed market forecast analysis, highlighting the current market size and the future growth potential associated with plant-based expression system market, during the period 2022-2035. Additionally, the chapter provides the likely distribution of the current and forecasted opportunity based on type of product (biosimilars, cell therapies, gene therapies, monoclonal antibodies, vaccines, and others). type of plant (algae, barley, benth, duckweed, lettuce, maize, moss, rice, tomato, tobacco, and wheat germ), type of expression system (stable expression system and transient expression system), region (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World).
How to2 months ago
How to2 months ago
